Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Xylazine: the lethal ingredient hiding in your pills

L. Joseph Parker, MD
Meds
May 21, 2024
Share
Tweet
Share

Xylazine has been found to be adulterating pills in America, and doctors will need to understand this new threat. First, xylazine is not “krokodil,” although it produces somewhat similar-looking skin ulcers.  Krokodil is a pseudonym for desomorphine, which is created from a precursor chemical called alpha-chlorocodide. Desomorphine is dihydrodesoxymorphine and was developed in Germany in 1932. It is a very fast but short-acting, semi-synthetic opioid used mainly in Russia.  Xylazine is completely different.

Xylazine was developed as an antihypertensive in 1962. In Germany again. It is not an opioid and is not based on the morphine molecule, but it does, in some studies, seem to bind the kappa-opiate receptor weakly. Xylazine is a near tricyclic, with a gap left in the middle ring. It is frequently mixed with other drugs like opiates to enhance their effects or with cocaine to ameliorate some of that drug’s more unpleasant effects. It has even been found in THC e-cigarettes in the United Kingdom.

So, how does Xylazine work? Once taken orally, xylazine spreads throughout the body in about half an hour, where it acts as an alpha-2  adrenergic agonist.  We usually think of adrenergic agonists as increasing alertness and blood pressure, but it’s more complicated than that. Because xylazine works on alpha-2 receptors, it has a paradoxical effect. It actually suppresses the release of these catecholamines, which was confusing to me.

Alpha-2 adrenergic receptors or adrenoreceptors are found in both the peripheral and central nervous system on both pre- and post-synaptic neurons and are usually activated by norepinephrine and epinephrine.  When the presynaptic alpha-2 neurons are activated, norepinephrine release onto the postsynaptic neuron where alpha-1 receptors reside is inhibited, reducing the activity of the post-synaptic neuron.  This prevents a “runaway” effect from these stimulatory neurotransmitters.

The effect is often referred to as sympatholytic, which means it reduces or blocks the sympathetic nervous system response, creating hypotension, bradycardia, sedation, analgesia, and muscle relaxation. Activation of alpha-2 adrenergic receptors also inhibits the release of other neurotransmitters, including glutamate, the major excitatory neurotransmitter in the brain, enhancing its overall sedative effect.

Medications with similar actions include tricyclic antidepressants (like trazodone),  phenothiazines (promethazine), and clonidine. Especially clonidine, which is also an alpha-2 agonist and is very similar to xylazine. There are three types of alpha-2 adrenoreceptors: a, b, and c.  Alpha-2a and 2c are in the locus ceruleus, and activating them shuts off norepinephrine in that area, creating the sedative effect. While in the dorsal horn of the spinal cord, alpha-2a, and c activation produces an analgesic effect.

The alpha-2b type is found in the smooth muscles of blood vessels, controlling blood pressure by vasodilation. Xylazine activates alpha-2 over alpha-1 by a factor of 160x. The selectivity for the subtypes of alpha-2 is still being worked out, but we do know that the activation of alpha-2b receptors in the skin, especially in an area of injection, causes vasoconstriction, which can lead to ischemia, leading to the pathognomonic skin ulcers.

These can occur from any administration of the drug and do not require skin injection to manifest but almost always occur with subcutaneous injection. Rapid and repeated use of xylazine at very high doses, in animals and humans, seems to exhaust the hypotensive action, creating a rebound hypertensive emergency.  This is something to be aware of as more Americans are unknowingly being poisoned by this drug every day and are at high risk of dying.

I stress poisoning because it’s important to remember that these are not “overdoses” as we usually think of them, as people do not know which “oxycodone” pills have been adulterated.  According to a CDC report, the rate of deaths involving xylazine has increased by 35x. I emphasize involvement because it does not mean there is a proven cause and effect.  Just because something is present doesn’t mean it was responsible for the death.

Multidrug intoxications are notoriously hard to treat, especially now with this new combination of fentanyl and xylazine. That’s because some medications work synergistically to multiply their effect rather than just being additive. Physicians can use this to reduce the overall dose of any one medicine in a practice called rational polypharmacy. In rational polypharmacy, we combine two medications that we know will amplify each other at lower doses to avoid the side effects associated with high-dose therapy.

It can also be used by illicit drug factories to create more potent combinations. That is what is happening with fentanyl and xylazine. In 2018, in the entire United States, there were only 102 deaths where xylazine was found with fentanyl. By 2021that became 3,468 and we should expect it to become more common. When 1,176 counterfeit pills were evaluated, most of them fell into three categories: Oxycodone (686 pills), alprazolam (brand name Xanax, 312 pills), and amphetamines (174 pills).

Terrifyingly, the laboratory analysis showed that almost all the counterfeit oxycodone pills seized in 2022 contained fentanyl.  Fentanyl was also detected in 2.6 percent of the Xanax pills.  None of the amphetamine pills contained fentanyl.  Xylazine was also found in almost all of the fake oxycodone pills. Out of 137 pills containing xylazine, 135 (98.5 percent) were counterfeit oxycodone while xylazine was detected with fentanyl in 136 of 137 pills.”

Dr. Kimberly Sue, an addiction medicine doctor at Yale Medicine in New Haven, Conn., said that “… for the majority of people, they don’t know they’re using it and they don’t intend to be using it …” Another complication is that xylazine does not respond to Narcan (naloxone), which is finally being made somewhat available about three decades later than it should have. This could dramatically limit EMT and ER treatments when patients are found alive.

ADVERTISEMENT

The combination of fentanyl with a new drug that cannot be treated with Narcan added to a medical environment where patients are abandoned after the DEA locks up their doctors for daring to try to treat pain and addiction, is a perfect storm for even more deaths. But it is worse than that. Xylazine alters mRNA expression of protein phosphorylating AMPK signaling molecules, which could cause persistent changes in the brain.

A study from 2022 found a critical role for AMPK in addiction, specifically to cocaine, through actions in the motivation and reinforcement center, the nucleus accumbens. Finding that “AMPK-CRTC1 signaling regulates cocaine reinforcement and motivation.” This could imply that xylazine, when added to any habit-forming substance, could potentiate the risk of developing a full addiction, dramatically increasing the dangers of its use.

But all is not lost. A vaccine has been developed by researchers at Scripps Research in La Jolla, California. This could be used after a non-fatal overdose to guard against the effects of relapse.  Can we make more of these vaccines? They have one for cocaine. Of at least one thing, I am sure. Addiction is more complicated than politicians would lead you to believe, and we need more doctors willing to try to help these patients, not fewer.

L. Joseph Parker is a distinguished professional with a diverse and accomplished career spanning the fields of science, military service, and medical practice. He currently serves as the chief science officer and operations officer, Advanced Research Concepts LLC, a pioneering company dedicated to propelling humanity into the realms of space exploration. At Advanced Research Concepts LLC, Dr. Parker leads a team of experts committed to developing innovative solutions for the complex challenges of space travel, including space transportation, energy storage, radiation shielding, artificial gravity, and space-related medical issues. 

He can be reached on LinkedIn and YouTube.

Prev

I was trolled by another physician on social media. I am happy I did not respond.

May 21, 2024 Kevin 0
…
Next

How choosing purpose over design transforms your life and destiny

May 21, 2024 Kevin 1
…

Tagged as: Medications

Post navigation

< Previous Post
I was trolled by another physician on social media. I am happy I did not respond.
Next Post >
How choosing purpose over design transforms your life and destiny

ADVERTISEMENT

More by L. Joseph Parker, MD

  • The shocking truth behind the DEA’s role in America’s pain crisis and doctor prosecutions

    L. Joseph Parker, MD
  • How the DEA’s use of predictive algorithms is worsening crises in urban communities and raising suicide rates among African Americans

    L. Joseph Parker, MD & Neil Anand, MD
  • Why good doctors are being jailed—and what it means for you

    L. Joseph Parker, MD

Related Posts

  • Colorful pills don’t paint my world

    Fery Pashang, PharmD
  • 4280: the number of pills Bob took last year

    Fery Pashang, PharmD
  • The ritual of taking medications: the pill wheel

    Fery Pashang, PharmD
  • Americans and Canadians use more post-surgery opioid pain pills

    Julie Appleby
  • Too many older adults are taking risky sedative medications

    Wendy Levinson, MD and Christine Soong, MD
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD

More in Meds

  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • Who will train the next generation of primary care clinicians without physician mentorship? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • The CDC’s restructuring: Where is the voice of health care in the room?

      Tarek Khrisat, MD | Policy
    • Choosing between care and country: a dual citizen’s Independence Day reflection

      Kathleen Muldoon, PhD | Policy
    • What Elon Musk and Diddy reveal about the price of power

      Osmund Agbo, MD | Conditions
    • 3 tips for using AI medical scribes to save time charting

      Erica Dorn, FNP | Tech

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • Who will train the next generation of primary care clinicians without physician mentorship? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • The CDC’s restructuring: Where is the voice of health care in the room?

      Tarek Khrisat, MD | Policy
    • Choosing between care and country: a dual citizen’s Independence Day reflection

      Kathleen Muldoon, PhD | Policy
    • What Elon Musk and Diddy reveal about the price of power

      Osmund Agbo, MD | Conditions
    • 3 tips for using AI medical scribes to save time charting

      Erica Dorn, FNP | Tech

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...